Newsfeeds - Spark Newswire

1 minute read

FDA Clears Moleculin’s IND Application To Conduct Phase 1 Study Of WP1066 For Recurrent Malignant Glioma

Today, 2:31 PM

Moleculin Biotech, Inc. (NASDAQ: MBRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent Malignant Glioma.

MBRX

1 minute read

FDA clears Moleculin’s IND application to Conduct Phase 1 Study of WP1066 for Recurrent Malignant Glioma

By Ragothaman Srinivasan

Today, 2:31 PM

Moleculin Biotech, Inc. (MBRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent Malignant Glioma The company plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label clinical study of oral WP1066 in adult patients.

MBRX

27 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 2:31 PM

During Tuesday's session, 454 stocks hit new 52-week lows.

ADAG

1 minute read

Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study

By Vandana Singh

Today, 2:31 PM

Moleculin Biotech Inc (NASDAQ: MBRX) has announced preliminary results supp

MBRX

4 minute read

Moleculin Announces Preliminary Third Cohort Interim Data In Phase 1b/2 Clinical Trial Of Annamycin For The Treatment Of Soft Tissue Sarcoma Lung Metastases

By Benzinga Newsdesk

Today, 2:31 PM

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,

MBRX

2 minute read

Moleculin Biotech Reports Received FDA Allowance To Begin Phase 1 Study Of WP1122 For Treatment Of Glioblastoma Multiforme

By Benzinga Newsdesk

Today, 2:31 PM

New US IND enables parallel development of WP1122 as a cancer therapy HOUSTON, Dec. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage

MBRX

1 minute read

Moleculin Biotech Q3 EPS $(0.15) Up From $(0.36) YoY

By Bill Haddad

Today, 2:31 PM

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.15) per share. This is a 58.33 percent increase over losses of $(0.36) per share from the same period last year.

MBRX

8 minute read

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

By Shanthi Rexaline

Today, 2:31 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)

ABIO

7 minute read

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results

By Shanthi Rexaline

Today, 2:31 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)

ADVM

1 minute read

Events
News

Moleculin Biotech To Present At Oppenheimer Fall Healthcare Life Sciences, MedTech Summit Sept. 20 At 4:35 p.m. EDT

By Benzinga Newsdesk

Today, 2:31 PM

Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that

MBRX